International Edition
Latest News
Health

Korean Study: Post-5-Year CT Scans Tied to 34% Lower Lung Cancer Mortality

A study of 55,694 Korean lung-cancer survivors who were alive and recurrence-free five years after diagnosis found that those who received a chest CT scan beyond the five-year mark had a 34% lower all-cause mortality rate than those…

Matthew Evison: New Study Challenges the Five-Year Lung Cancer Follow-Up Limit

A study of 55,694 Korean lung-cancer survivors who were alive and recurrence-free five years after diagnosis found that those who received a chest CT scan beyond the five-year mark had a 34% lower all-cause mortality rate than those who did not, according to research published in JAMA Oncology. The hazard ratio was 0.66.

The analysis, led by Dong Woog Yoon of Samsung Medical Center and colleagues, used Korean national data and a sequential target-trial emulation design. Survivors who underwent post-five-year CT scans had a higher annual rate of detected lung-cancer events — recurrence or a new primary — at 2.49% versus 1.97% in those not scanned. When an event was found, scanned patients more often underwent surgical resection.

Matthew Evison, professor of respiratory medicine at the University of Manchester and associate medical director at Greater Manchester Cancer Alliance, said the mortality difference is too large to be explained by scanning alone. Scanned patients had about 1.7 fewer deaths per 100 person-years but only about 0.5 extra cancer events detected per year.

“That points to healthier, more engaged patients being the ones who get scanned, as the authors acknowledge.”

Matthew Evison, professor of respiratory medicine at the University of Manchester and associate medical director at Greater Manchester Cancer Alliance, said.

The strongest mortality signals appeared in women, never-smokers and older adults — groups that in the United Kingdom fall outside lung-cancer screening programmes once hospital follow-up ends. Evison said that indolent, slow-growing disease is common in East Asian populations, making overdiagnosis a real possibility.

Led by Dong Woog Yoon of Samsung Medical Center, a tertiary referral hospital that operated 1,766 beds and employed 915 physicians as of 31 December 2024, the study analyzed a national cohort of 55,694 lung-cancer survivors.

The institution, which has served as the teaching hospital of Sungkyunkwan University School of Medicine since 1997, houses the Samsung Comprehensive Cancer Center — opened in 2008 — and achieved Stage 7 validation, the highest level, under all four Healthcare Information and Management Systems Society maturity models.

Evison described the paper as hypothesis-generating rather than practice-changing, but said it sharpens a question patients ask weekly: what happens after five years? He called for consensus and ideally a trial. The study was published in JAMA Oncology in 2026 (doi:10.1001/jamaoncol.2026.4659).

About the author: Health Desk

Health Desk at Archynewsy.